LP-300
Asset
Modulates cellular redox pathways to enhance tumor sensitivity to chemotherapy.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Oxidative stress and ROS signalling
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Non-small cell lung cancer
Phase 2, businesswire.com, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors6
Every asset’s record: target, stage, trials and the evidence behind it.